EG 427 Raises €27 Million in Series B Funding for Genetic Medicines

Deal News | Feb 20, 2025 | Goodwin

Bpifrance and Andera Partners have invested in a €27 million Series B financing round for EG 427, a biotechnology firm specializing in genetic medicines for prevalent chronic neurological diseases. The Paris-based Life Sciences team from Goodwin advised on the investment, which was co-led by Andera Partners and Bpifrance under the InnoBio strategy. The raised funds will focus on advancing clinical studies and developing the company’s specialized platform for pinpoint genetic therapies. Key advisors from Goodwin included Anne-Charlotte Rivire, Johann Gandilhon, and Charlotte Muller on corporate aspects and Marie Fillon, Louis de Chezelles, and Albana Taipi on intellectual property (IP) aspects.

Sectors

  • Biotechnology
  • Investment Management
  • Legal Services

Geography

  • France – The investment involves French companies and advisory firms, including EG 427 and Paris-based legal advisors from Goodwin. Bpifrance and Andera Partners are also based in France.

Industry

  • Biotechnology – EG 427 operates in the biotechnology sector, focusing on innovative genetic medicines for neurological diseases.
  • Investment Management – Bpifrance and Andera Partners are involved in the investment management industry, providing capital to innovative ventures like EG 427.
  • Legal Services – Goodwin provides legal advisory services in the transaction, demonstrating the role of legal professionals in investment activities.

Financials

  • €27 Million – The total amount raised during the Series B financing round for EG 427.

Participants

NameRoleTypeDescription
EG 427Target CompanyCompanyA biotechnology company developing genetic medicines for chronic neurological diseases.
BpifranceInvestorCompanyA French investment bank involved in financing businesses at various stages of growth.
Andera PartnersInvestorCompanyA private equity firm that co-led the Series B financing of EG 427.
GoodwinLegal AdvisorCompanyA law firm advising on the corporate and intellectual property aspects of the investment deal.